Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageDiabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition known as hyperglycemia, and very low levels, a condition called hypoglycemia.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Business segments
Q1 2026 · $761.8MThe company’s own SEC segment disclosure.
- U.S.Omnipod$515.6M68%
- International Omnipod$242.9M32%
- Drug Delivery$3.3M0%
Insulet Corporation (PODD) reported revenue of $802M in Q2 2026 (quarter ended June 30, 2026), up 24% from the same quarter a year earlier. That came with a gross margin of 70% and net income of $95M (12% of revenue). For the full year FY2025, revenue was $2.71B (+31% year on year) and net income $247M. Its largest product in 2026-Q1 was U.S.Omnipod at $516M, 68% of the disclosed total, just ahead of International Omnipod at 32%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.